These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

447 related articles for article (PubMed ID: 24646861)

  • 21. Dose-finding study of bixalomer in patients with chronic kidney disease on hemodialysis with hyperphosphatemia: a double-blind, randomized, placebo-controlled and sevelamer hydrochloride-controlled open-label, parallel group study.
    Akizawa T; Origasa H; Kameoka C; Kaneko Y; Kanoh H
    Ther Apher Dial; 2014 Jun; 18 Suppl 2():24-32. PubMed ID: 24975892
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sevelamer carbonate lowers serum phosphorus effectively in haemodialysis patients: a randomized, double-blind, placebo-controlled, dose-titration study.
    Chen N; Wu X; Ding X; Mei C; Fu P; Jiang G; Li X; Chen J; Liu B; La Y; Hou F; Ni Z; Fu J; Xing C; Yu X; Huang C; Zuo L; Wang L; Hunter J; Dillon M; Plone M; Neylan J
    Nephrol Dial Transplant; 2014 Jan; 29(1):152-60. PubMed ID: 24151017
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A Randomized Trial of Tenapanor and Phosphate Binders as a Dual-Mechanism Treatment for Hyperphosphatemia in Patients on Maintenance Dialysis (AMPLIFY).
    Pergola PE; Rosenbaum DP; Yang Y; Chertow GM
    J Am Soc Nephrol; 2021 Jun; 32(6):1465-1473. PubMed ID: 33766811
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and tolerability of sevelamer carbonate in hyperphosphatemic patients who have chronic kidney disease and are not on dialysis.
    Ketteler M; Rix M; Fan S; Pritchard N; Oestergaard O; Chasan-Taber S; Heaton J; Duggal A; Kalra PA
    Clin J Am Soc Nephrol; 2008 Jul; 3(4):1125-30. PubMed ID: 18450923
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of calcium acetate/magnesium carbonate as a phosphate binder compared with sevelamer hydrochloride in haemodialysis patients: a controlled randomized study (CALMAG study) assessing efficacy and tolerability.
    de Francisco AL; Leidig M; Covic AC; Ketteler M; Benedyk-Lorens E; Mircescu GM; Scholz C; Ponce P; Passlick-Deetjen J
    Nephrol Dial Transplant; 2010 Nov; 25(11):3707-17. PubMed ID: 20530499
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical effects of the new phosphorus binder, bixalomer in hemodialysis patients switched from sevelamer hydrochloride.
    Gen S; Sasaki T; Saito K; Nobe K; Nodaira Y; Ikeda N
    Ther Apher Dial; 2014 Jun; 18 Suppl 2():8-12. PubMed ID: 24975889
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and safety of sevelamer carbonate in hyperphosphatemic pediatric patients with chronic kidney disease.
    Fathallah-Shaykh S; Drozdz D; Flynn J; Jenkins R; Wesseling-Perry K; Swartz SJ; Wong C; Accomando B; Cox GF; Warady BA
    Pediatr Nephrol; 2018 Feb; 33(2):325-333. PubMed ID: 28900759
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost Effectiveness of Sucroferric Oxyhydroxide Compared with Sevelamer Carbonate in the Treatment of Hyperphosphataemia in Patients Receiving Dialysis, from the Perspective of the National Health Service in Scotland.
    Gutzwiller FS; Pfeil AM; Ademi Z; Blank PR; Braunhofer PG; Szucs TD; Schwenkglenks M
    Pharmacoeconomics; 2015 Dec; 33(12):1311-24. PubMed ID: 26334991
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Sucroferric oxyhydroxide, a novel iron-based phosphate binder. Which current use in dialysis patients?].
    Bataille P; Delattre V; Daroux M
    Nephrol Ther; 2017 Apr; 13 Suppl 1():S103-S108. PubMed ID: 28577730
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The effects of colestilan versus placebo and sevelamer in patients with CKD 5D and hyperphosphataemia: a 1-year prospective randomized study.
    Locatelli F; Spasovski G; Dimkovic N; Wanner C; Dellanna F; Pontoriero G
    Nephrol Dial Transplant; 2014 May; 29(5):1061-73. PubMed ID: 24302608
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and safety of sevelamer hydrochloride and calcium acetate in patients on peritoneal dialysis.
    Evenepoel P; Selgas R; Caputo F; Foggensteiner L; Heaf JG; Ortiz A; Kelly A; Chasan-Taber S; Duggal A; Fan S
    Nephrol Dial Transplant; 2009 Jan; 24(1):278-85. PubMed ID: 18820280
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy of sucroferric oxyhydroxide treatment in Japanese hemodialysis patients and its effect on gastrointestinal symptoms.
    Suzuki D; Ichie T; Hayashi H; Sugiura Y; Sugiyama T
    Pharmazie; 2017 Feb; 72(2):118-122. PubMed ID: 29441865
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sucroferric oxyhydroxide for hyperphosphatemia: a review of real-world evidence.
    Coyne DW; Sprague SM; Vervloet M; Ramos R; Kalantar-Zadeh K
    J Nephrol; 2022 Apr; 35(3):875-888. PubMed ID: 35138627
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and Safety of Sucroferric Oxyhydroxide and Calcium Carbonate in Hemodialysis Patients.
    Koiwa F; Yokoyama K; Fukagawa M; Akizawa T
    Kidney Int Rep; 2018 Jan; 3(1):185-192. PubMed ID: 29340330
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A comparative study of phosphate binders in patients with end stage kidney disease undergoing hemodialysis.
    Prajapati VA; Galani VJ; Shah PR
    Saudi J Kidney Dis Transpl; 2014 May; 25(3):530-8. PubMed ID: 24821148
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A Review of Phosphate Binders in Chronic Kidney Disease: Incremental Progress or Just Higher Costs?
    St. Peter WL; Wazny LD; Weinhandl E; Cardone KE; Hudson JQ
    Drugs; 2017 Jul; 77(11):1155-1186. PubMed ID: 28584909
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sucroferric oxyhydroxide for the treatment of hyperphosphatemia.
    Sprague SM; Floege J
    Expert Opin Pharmacother; 2018 Jul; 19(10):1137-1148. PubMed ID: 29985725
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Novel phosphate binders: plus ça change, plus c'est la même chose.
    Hutchison AJ
    Kidney Int; 2014 Sep; 86(3):471-4. PubMed ID: 25168499
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Randomized controlled trial of bixalomer versus sevelamer hydrochloride in hemodialysis patients with hyperphosphatemia.
    Akizawa T; Origasa H; Kameoka C; Kaneko Y; Kawasaki S;
    Ther Apher Dial; 2014 Apr; 18(2):122-31. PubMed ID: 24720402
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A safety evaluation of sucroferric oxyhydroxide for the treatment of hyperphosphatemia.
    Sprague SM; Ketteler M
    Expert Opin Drug Saf; 2021 Dec; 20(12):1463-1472. PubMed ID: 34511018
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.